DisclosureWe earn commission on partner links; ranking is set by our evidence-based methodology — not advertisers. Read policy
An online platform pairing video therapy and medication management with a precision-prescribing model and weekly symptom tracking for anxiety and depression.
A data-driven psychiatry platform that delivers for depression and anxiety
Brightside Health stands out among telehealth mental-health services because it publishes peer-reviewed outcomes and ties every visit to PHQ-9/GAD-7 symptom tracking. For uncomplicated depression or anxiety, it offers fast, evidence-based medication management and therapy. It is not the right fit if you need controlled substances, bipolar I care, or in-person crisis support.
We may earn a commission if you buy through this link, at no extra cost to you. It never affects our score. How we make money
Independent third-party ratings, shown for context. Not affiliated with HealthVetted scoring.
Brightside Health is an online (telehealth) mental-health company founded in 2017 and headquartered in San Francisco. Its co-founders include CEO Brad Kittredge (previously a product leader at 23andMe and Lantern) and Chief Medical Officer Dr. Mimi Winsberg, a Stanford-trained psychiatrist. Unlike a generic "find a therapist" marketplace, Brightside is a structured care platform: it employs or contracts licensed psychiatric providers (psychiatrists, psychiatric nurse practitioners) and master's- or doctoral-level therapists, and routes patients through a standardized intake and measurement-based treatment process.
The flow is consistent and largely asynchronous between live appointments:
Brightside focuses on depression, anxiety, and related conditions. Providers may also treat areas such as OCD, insomnia, PTSD, and bipolar II, and the company runs virtual intensive outpatient programming (IOP) in select states. Crucially, Brightside is not built for everyone: it excludes people with psychosis, schizophrenia, or bipolar I disorder at intake, does not treat ADHD, and does not prescribe controlled substances — no benzodiazepines like Xanax or Ativan, and no stimulants like Adderall or Ritalin. That last point is a meaningful safety and scope decision that separates it from some "get a prescription fast" competitors.
The core intellectual property is a proprietary clinical-decision-support system the company calls precision prescribing (sometimes "PrecisionRx"). When a prescriber considers medication, the tool analyzes intake data — symptom profile, history, prior medication responses, and side-effect sensitivities — against a database of outcomes from Brightside's own patient population to suggest the antidepressant and dose most likely to be both effective and tolerable for that individual.
It is important to be precise about what this is and is not. It is not pharmacogenomic (DNA) testing, and it is not a fully automated algorithm prescribing on its own — a licensed clinician makes the final decision and can override the suggestion. It is best understood as data-driven decision support layered on top of measurement-based care, intended to shorten the trial-and-error that typically defines antidepressant treatment. The medications themselves are standard, evidence-based, generically available drugs (SSRIs, SNRIs, and adjuncts), so the value proposition is not exotic pharmacology but smarter matching and tighter follow-up.
A second, related concept is "early response." Brightside has published analyses arguing that a patient's symptom trajectory in the first few weeks is a meaningful predictor of eventual outcome — which, if used well, lets providers switch non-responders sooner rather than leaving them on an ineffective drug for months.
Brightside is unusually transparent for a direct-to-consumer telehealth company in that it has published real-world outcome data in peer-reviewed journals. That is a genuine strength — but the studies have real limitations that any honest reader should understand.
The flagship outcomes study (BMC Psychiatry, 2022; PMID 35854281). Researchers analyzed 6,248 Brightside patients who completed at least 12 weeks of treatment for depression and/or anxiety between October 2018 and April 2021. Among the findings: roughly 90% of patients met the threshold for clinically meaningful symptom improvement, and a majority reached remission (PHQ-9 scores below the clinical cutoff), with substantial mean reductions in PHQ-9 and GAD-7 scores over the 12 weeks.
Those numbers look impressive, and the authors themselves were careful to flag why they should be read cautiously. The study was not a randomized controlled trial — there was no comparison or placebo group, so improvement cannot be cleanly attributed to Brightside versus the natural course of illness, regression to the mean, or placebo effects. The sample was self-selected (people who chose and could afford the service and stuck with it for 12 weeks), which excludes dropouts and likely inflates results. The population skewed toward white, female, and relatively higher-functioning patients, and outcomes relied on self-reported questionnaires rather than clinician-administered scales. In other words, these are encouraging real-world signals, not proof of superiority over standard in-person care.
Suicide-risk outcomes (Crisis Care). Brightside also operates a Suicide Prevention Program (formerly "Crisis Care"), a structured program of roughly 12 sessions over about 16 weeks for adults with elevated suicide risk, built on the Collaborative Assessment and Management of Suicidality (CAMS) framework — itself an evidence-based model supported by multiple randomized trials in traditional settings. Brightside published a feasibility-and-effectiveness analysis of the program (in the journal Healthcare (Basel), 2023; PMID 38132048), reporting that patients who graduated from the program showed roughly a 71% reduction in the frequency of suicidal thinking, with declines in suicidal ideation, depression, and anxiety across patient subgroups. Again, this is promising and addresses a population most telehealth companies actively screen out — but it is a preliminary feasibility study with no control group, not a definitive trial, and the program is only available in a subset of states.
The honest bottom line on efficacy: Brightside delivers standard, well-supported treatments (FDA-approved antidepressants and CBT-based therapy) through a tightly measured, well-followed-up model, and its own data suggest outcomes in the same range you'd hope for from good guideline-concordant care. The "precision prescribing" branding should be treated as a reasonable system for organizing care, not as a clinically proven leap beyond what an attentive psychiatrist practicing measurement-based care would achieve.
Good fit:
Should look elsewhere:
Pricing depends heavily on whether you use insurance. As of 2025–2026, the published self-pay (cash) rates are:
Medication, if filled through Brightside's mail-order pharmacy, is roughly $15 per fill or your insurance copay; local-pharmacy pickups aren't billed through Brightside, and uninsured patients can sometimes do better with a GoodRx-type coupon.
Insurance is the big variable. Brightside accepts many major insurers — including Aetna, Cigna, Anthem, and UnitedHealthcare — in select states, and has expanded into some Medicare and Medicaid plans for psychiatry, with insurance-based access available across all 50 states and Washington, D.C. With in-network coverage, your out-of-pocket cost can drop to a standard copay, sometimes substantially below the cash prices above. The practical caveats: exactly which plans are in-network varies by state and changes over time, the therapy-only cash price is on the higher end of the online-therapy market, and the headline "$95" psychiatry figure assumes you have prescription benefits — so verify your specific coverage before enrolling rather than relying on advertised numbers.
Yes, in the sense that matters most: care is delivered by licensed clinicians, treatment uses validated screening tools and standard evidence-based medications and therapy, and the company has subjected its outcomes to peer review. Several attributes stand out on the safety side:
What to watch for as a consumer: telehealth medication management is only as good as the follow-up, so engage with the messaging and re-assessments rather than treating it as a "set it and forget it" prescription. Confirm your provider's licensure and your state's availability, understand the cancellation and subscription terms, and remember that asynchronous messaging is not a substitute for emergency care.
For someone whose primary need is depression or anxiety management with strong follow-up, Brightside is generally the more clinically serious option; for people needing ADHD care, controlled substances, or a wide choice of long-term therapists, competitors fit better.
Brightside Health is a credible, clinically oriented telehealth option for adults (and some teens) dealing with depression and anxiety, with two standout strengths: a structured, measurement-based model with published peer-reviewed outcomes, and a willingness to treat higher-risk patients through an evidence-based suicide-prevention program. Its decision not to prescribe controlled substances and to screen out conditions it can't safely manage is a mark of clinical responsibility, not a limitation to hold against it.
The honest caveats are equally real: its outcome data, while encouraging, comes from observational, self-selected populations rather than randomized trials, so "precision prescribing" should be read as smart, well-followed-up standard care rather than a proven breakthrough; cash therapy pricing runs high; and insurance coverage — the single biggest factor in what you'll actually pay — varies by state and plan. Verify your coverage and confirm Brightside treats your specific condition before committing. And if you are in crisis, do not wait on a telehealth appointment — call or text 988 immediately.
Brightside is a telehealth platform connecting adults to licensed psychiatric providers and therapists by video and messaging. After a free online assessment, its PrecisionRx clinical-decision-support tool analyzes your symptom pattern against large treatment-outcome datasets to suggest medication options for your prescriber to consider. Care is "measurement-based": you complete standardized PHQ-9 (depression) and GAD-7 (anxiety) questionnaires at intake and at regular intervals, so providers adjust treatment based on tracked scores rather than memory alone. Therapy uses evidence-based approaches such as CBT, supplemented by structured video lessons.
Brightside has published several peer-reviewed studies, though most are observational and authored by Brightside-affiliated researchers rather than independent randomized trials. A 2022 retrospective analysis in BMC Psychiatry of 6,248 patients who completed at least 12 weeks of medication treatment found about 90% had clinically meaningful improvement on PHQ-9 or GAD-7 and about 75% reached remission (scores below 10); in the larger intent-to-treat sample these figures were lower (roughly 74% improvement and 59% remission), and about 78.9% of patients started treatment within 4 days. A 2022 JMIR Formative Research longitudinal study of 8,581 patients reported the treatment group was about 4.3 times more likely to achieve suicidal-ideation remission (odds ratio 4.31), with a predictive model 77% accurate in classifying complete remission. Because these are single-platform, observational studies, results may not generalize and individual outcomes vary.
A realistic timeline of what Brightside Health users typically experience. Individual results vary; this is educational, not medical advice.
You complete a free online questionnaire (Brightside says its intake captures 100+ data points) about your symptoms and goals and whether you're open to therapy, medication, or both. You immediately see a personalized recommendation, then create an account and book a visit. No diagnosis or prescription happens at this stage.
Same- or next-day appointments are often available, and Brightside reports 68% of therapy users get a first session within 3 days. The initial visit runs about 30 minutes: a psychiatric provider reviews your history before any diagnosis, or a therapist explores your background and goals. If medication is appropriate, the provider uses their decision-support tool (PrecisionRx) to choose a starting option; results vary by person.
If you're on medication, you typically begin at a low dose. Weekly self-reported check-ins (based on the PHQ-9 and GAD-7) let your provider track symptoms and side effects; early side effects like nausea or sleep changes often ease within the first couple of weeks. Therapy clients usually meet roughly weekly (follow-ups about 55 minutes). Messages to your provider are answered within 72 hours, but dose changes require a scheduled visit.
Antidepressants generally take time to build up, so meaningful change is not expected immediately. Brightside's own research suggests an early response at 2-4 weeks can predict later remission, but many people feel little change this early. Keep up the weekly check-ins so your provider can spot what's working. In therapy, you may start applying coping skills, though progress is gradual.
This is the typical point to judge medication effectiveness. If you're not feeling better by 6-8 weeks, your provider may adjust the dose or switch medications; some people need more than one try to find the right fit. Results vary widely and there are no guarantees.
Twelve weeks is a common checkpoint for assessing full benefit; Brightside reports that 86% of members see clinically significant improvement and 71% reach remission by this point (company-reported outcomes, not a guarantee for any individual). For maintenance, providers typically recommend continuing medication for about 9-12 months with video visits at least every 3 months, then tapering when appropriate under medical guidance. Never stop medication abruptly on your own.
Brightside itself is a care-delivery service, so "side effects" come from the prescribed medications, typically SSRIs, SNRIs, or bupropion. Common, often temporary effects include nausea, headache, drowsiness or insomnia, dry mouth, dizziness, sexual dysfunction, and appetite or weight changes. Serious but rarer risks include serotonin syndrome, abnormal bleeding, hyponatremia, and worsening mood or new or increased suicidal thoughts, which carry an FDA boxed warning for antidepressants in people under 25, especially early in treatment or after dose changes. Bupropion can lower the seizure threshold. Seek urgent help for suicidal thoughts, severe agitation, or signs of an allergic reaction, and discuss your full medication list and history with your prescriber.
Starts at $95/mo from Brightside Health.
As of 2026, self-pay pricing is roughly $95/month for psychiatry (medication management), $299/month for therapy (four video sessions plus unlimited messaging), and about $349/month for combined psychiatry plus therapy. Medications are billed separately: Brightside's mail-order pharmacy is about $15 per fill or your copay if your Rx benefits are accepted, or you can use a local pharmacy or GoodRx. Brightside accepts many major insurers (Aetna, Cigna, Anthem, UnitedHealthcare, and some Medicare/Medicaid plans); with coverage, out-of-pocket can drop to typical copays (often about $15-$30 per session), though actual cost depends on your deductible and plan. Verify your specific coverage before enrolling, since billing surprises are a frequent complaint.
Prices current as of May 29, 2026 and exclude promo codes; cash-pay and channel pricing change frequently — confirm with the pharmacy or provider.
If you have moderate depression or anxiety and want structured, measurement-based psychiatry or therapy from home, Brightside is one of the more clinically rigorous options, backed by published remission data. Expect roughly $95-$349/month before insurance, plus separate pharmacy costs. Skip it if you need stimulants, benzodiazepines, bipolar I treatment, or are sensitive to billing issues, which are the most common complaint.
Yes. Brightside Health is a legitimate, established telehealth company with licensed US providers and multiple peer-reviewed published studies on its outcomes. It is not BBB accredited and has a number of billing and customer-service complaints, but the criticisms center on billing and support rather than clinical quality.
Yes. Brightside accepts many major insurers including Aetna, Cigna, Anthem, and UnitedHealthcare, plus some Medicare and Medicaid plans. With coverage your cost can fall to a typical copay (often around $15-$30 per session), but always verify your specific plan before enrolling because actual cost depends on your deductible and benefits.
As of 2026, self-pay runs about $95/month for psychiatry, $299/month for therapy, and roughly $349/month for both combined. Medications are billed separately, about $15 per fill through Brightside's mail-order pharmacy (or your copay), or you can use a local pharmacy or GoodRx.
No. Brightside does not prescribe controlled substances, including stimulants like Adderall and Ritalin or benzodiazepines like Xanax, Klonopin, and Ativan. It focuses on antidepressants and other non-controlled medications for depression and anxiety, and can offer non-stimulant options for ADHD.
Only partially. Brightside generally does not treat bipolar I or active mania and will refer those patients elsewhere, though providers may treat some cases of bipolar II alongside depression and anxiety. If you have bipolar I, in-person psychiatric care is recommended.
Company-published studies are encouraging: a 6,248-patient analysis found about 90% of patients completing 12 weeks had clinically meaningful improvement and roughly 75% reached remission. However, these are observational, company-authored studies rather than independent randomized trials, and outcomes are lower in the broader intent-to-treat sample, so individual results vary.
Quickly for telehealth: company research reports nearly 79% of patients begin treatment within about 4 days of enrolling. You complete a free online assessment, then book a video evaluation with a provider, often within a few days.
Brightside has a dedicated Crisis Care program, and company research reported patients were about 4.3 times more likely to achieve suicidal-ideation remission, but it is not for active, life-threatening emergencies. If you are in immediate danger, call or text 988 (the US Suicide and Crisis Lifeline) or 911.
Brightside typically prescribes non-controlled psychiatric medications such as SSRIs, SNRIs, and bupropion, selected with input from its PrecisionRx decision-support tool. The specific medication and dosing are decided individually by your licensed prescriber based on your symptoms and tracked scores.
Affiliate link — we may earn a commission at no extra cost to you, and it never changes our rankings or score. Disclosure
Same-category options, scored on the same six-axis rubric. Higher is better.